Emergent BioSolutions | EBS - Ebitda


Emergent BioSolutions reported $-113.5M in EBITDA for its fiscal quarter ending in March of 2023.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Exelixis USD 258.29M 15.43M Mar/2026
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Lonza CHF 1.01B 54M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Myriad Genetics USD 14.3M 4M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pacira USD 40.24M 1.53M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Sanofi EUR 3.31B 3.65B Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Xoma USD 2.52M 7.98M Jun/2024